ONCOLYTICS BIOTECH INC 8-K

What Happened

• On January 15, 2026, Oncolytics Biotech Inc. (ONCY) held a Special Meeting of Shareholders and announced that shareholders approved three special resolutions: (1) continuance from Alberta to British Columbia, (2) domestication from British Columbia to the State of Nevada, and (3) adoption of the Oncolytics Biotech Inc. 2026 Incentive Award Plan. Proxies were solicited under the company’s Circular/Prospectus; 17,596,480 common shares were present or represented by proxy (16.35% of 107,606,376 outstanding shares as of the December 9, 2025 record date).

Key Details

• Meeting date: January 15, 2026; record date: December 9, 2025.
• Shareholder turnout: 17,596,480 shares represented = 16.35% of outstanding common shares (107,606,376).
• Vote results (For / Against / Abstain):
  • Continuance to British Columbia: 14,994,075 / 2,602,405 / 0.
  • Domestication to Nevada: 15,304,574 / 2,291,905 / 0.
  • 2026 Incentive Award Plan: 13,508,657 / 4,087,822 / 0.
• The continuance and domestication approvals are conditional on each other and on implementation as described in the Circular/Prospectus. The company issued a press release reporting the results (filed as Exhibit 99.1).

Why It Matters

• The approved continuance and domestication change the company’s legal home from Canada to the U.S. (Nevada), which will shift the company’s governing law and regulatory jurisdiction once implemented — an important corporate-governance and legal change for investors to monitor.
• Approval of the 2026 Incentive Award Plan authorizes a new equity/award framework for compensating or incentivizing employees, directors or consultants, which can affect dilution and executive compensation going forward.
• Voter participation was relatively low (16.35% of outstanding shares), so investors should watch for further disclosures about implementation steps, timing of the domiciliation, and any filings that follow.